Pasithea Therapeutics Shares Are Trading Higher After the Company Announced Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics 公布了来自 NRAS 突变癌症异种移植模型的 PAS-004 的临床前疗效数据后,股价上涨
Pasithea Therapeutics Shares Are Trading Higher After the Company Announced Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics 公布了来自 NRAS 突变癌症异种移植模型的 PAS-004 的临床前疗效数据后,股价上涨
使用浏览器的分享功能,分享给你的好友吧